{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:08:54Z","timestamp":1790665734321,"version":"4.1.0"},"reference-count":341,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s10555-023-10079-1","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T13:04:34Z","timestamp":1673701474000},"page":"113-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Role of myeloid-derived suppressor cells in tumor recurrence"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0452-9636","authenticated-orcid":false,"given":"Kathryn","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-8786","authenticated-orcid":false,"given":"Zaid","family":"Al-Kadhimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-6056","authenticated-orcid":false,"given":"James E.","family":"Talmadge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"10079_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.soncn.2017.02.009","volume":"33","author":"C Coleman","year":"2017","unstructured":"Coleman, C. (2017). Early detection and screening for breast cancer. Seminars in Oncology Nursing, 33, 141\u2013155.","journal-title":"Seminars in Oncology Nursing"},{"key":"10079_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.7326\/M16-2586","volume":"167","author":"A Tsodikov","year":"2017","unstructured":"Tsodikov, A., et al. (2017). Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Annals of Internal Medicine, 167, 449\u2013455.","journal-title":"Annals of Internal Medicine"},{"key":"10079_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nm.4091","volume":"22","author":"TG Bivona","year":"2016","unstructured":"Bivona, T. G., & Doebele, R. C. (2016). A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nature Medicine, 22, 472\u2013478.","journal-title":"Nature Medicine"},{"issue":"35","key":"10079_CR4","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1200\/JCO.2018.78.9032","volume":"36","author":"A Dasari","year":"2018","unstructured":"Dasari, A., Grothey, A., & Kopetz, S. (2018). Circulating tumor DNA-defined minimal residual disease in solid tumors: Opportunities to accelerate the development of adjuvant therapies. Journal Clinical Oncology, 36(35), 3437.","journal-title":"Journal Clinical Oncology"},{"key":"10079_CR5","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.1158\/1078-0432.CCR-10-2574","volume":"17","author":"MS Sosa","year":"2011","unstructured":"Sosa, M. S., Avivar-Valderas, A., Bragado, P., Wen, H. C., & Aguirre-Ghiso, J. A. (2011). ERK1\/2 and p38alpha\/beta signaling in tumor cell quiescence: Opportunities to control dormant residual disease. Clinical Cancer Research, 17, 5850\u20135857.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrc3910","volume":"15","author":"CM Ghajar","year":"2015","unstructured":"Ghajar, C. M. (2015). Metastasis prevention by targeting the dormant niche. Nature Reviews Cancer, 15, 238\u2013247.","journal-title":"Nature Reviews Cancer"},{"key":"10079_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2013.10.029","volume":"155","author":"FG Giancotti","year":"2013","unstructured":"Giancotti, F. G. (2013). Mechanisms governing metastatic dormancy and reactivation. Cell, 155, 750\u2013764.","journal-title":"Cell"},{"key":"10079_CR8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7, 834\u2013846.","journal-title":"Nature Reviews Cancer"},{"key":"10079_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3793","volume":"14","author":"MS Sosa","year":"2014","unstructured":"Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014). Mechanisms of disseminated cancer cell dormancy: An awakening field. Nature Reviews Cancer, 14, 611\u2013622.","journal-title":"Nature Reviews Cancer"},{"key":"10079_CR10","doi-asserted-by":"publisher","first-page":"R577","DOI":"10.1530\/ERC-18-0142","volume":"25","author":"A Nicolini","year":"2018","unstructured":"Nicolini, A., Ferrari, P., Rossi, G., & Carpi, A. (2018). Tumour growth and immune evasion as targets for a new strategy in advanced cancer. Endocrine-Related Cancer, 25, R577\u2013R604.","journal-title":"Endocrine-Related Cancer"},{"key":"10079_CR11","first-page":"252","volume":"64","author":"CE DeSantis","year":"2014","unstructured":"DeSantis, C. E., et al. (2014). Cancer treatment and survivorship statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 252\u2013271.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10079_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/cancers11081207","volume":"11","author":"R Jahanban-Esfahlan","year":"2019","unstructured":"Jahanban-Esfahlan, R., et al. (2019). Tumor cell dormancy: Threat or opportunity in the fight against cancer. Cancers (Basel), 11, 1207.","journal-title":"Cancers (Basel)"},{"key":"10079_CR13","first-page":"3584","volume":"38","author":"JM Yuhas","year":"1978","unstructured":"Yuhas, J. M., & Tarleton, A. E. (1978). Dormancy and spontaneous recurrence of human breast cancer in vitro. Cancer Research, 38, 3584\u20133589.","journal-title":"Cancer Research"},{"key":"10079_CR14","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1158\/0008-5472.CAN-14-2406","volume":"74","author":"I Romero","year":"2014","unstructured":"Romero, I., Garrido, F., & Garcia-Lora, A. M. (2014). Metastases in immune-mediated dormancy: A new opportunity for targeting cancer. Cancer Research, 74, 6750\u20136757.","journal-title":"Cancer Research"},{"key":"10079_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S0002-9440(10)65628-3","volume":"153","author":"KJ Luzzi","year":"1998","unstructured":"Luzzi, K. J., et al. (1998). Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. American Journal of Pathology, 153, 865\u2013873.","journal-title":"American Journal of Pathology"},{"key":"10079_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nm.2328","volume":"17","author":"MJ Bissell","year":"2011","unstructured":"Bissell, M. J., & Hines, W. C. (2011). Why don\u2019t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Medicine, 17, 320\u2013329.","journal-title":"Nature Medicine"},{"key":"10079_CR17","doi-asserted-by":"publisher","first-page":"12396","DOI":"10.1073\/pnas.1106613108","volume":"108","author":"JW Uhr","year":"2011","unstructured":"Uhr, J. W., & Pantel, K. (2011). Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A, 108, 12396\u201312400.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10079_CR18","doi-asserted-by":"crossref","unstructured":"Willis, R. (1934) The spread of tumours in the human body. By Rupert A. Willis. M.D., B.S., D.Sc. (Melbourne), 1934 London: J. & A. Churchill. 25s. net. BJS (British Journal of Surgery), 22, 196\u2013196.","DOI":"10.1002\/bjs.1800228544"},{"key":"10079_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/bmj.2.4888.607","volume":"J2","author":"G Hadfield","year":"1954","unstructured":"Hadfield, G. (1954). The dormant cancer cell. Br Med, J2, 607\u2013610.","journal-title":"Br Med"},{"key":"10079_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM200002243420801","volume":"342","author":"S Braun","year":"2000","unstructured":"Braun, S., et al. (2000). Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. New England Journal of Medicine, 342, 525\u2013533.","journal-title":"New England Journal of Medicine"},{"key":"10079_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMoa050434","volume":"353","author":"S Braun","year":"2005","unstructured":"Braun, S., et al. (2005). A pooled analysis of bone marrow micrometastasis in breast cancer. New England Journal of Medicine, 353, 793\u2013802.","journal-title":"New England Journal of Medicine"},{"key":"10079_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4137\/CGM.S31244","volume":"8","author":"S Friberg","year":"2015","unstructured":"Friberg, S., & Nystrom, A. (2015). Cancer metastases: Early dissemination and late recurrences. Cancer Growth Metastasis, 8, 43\u201349.","journal-title":"Cancer Growth Metastasis"},{"key":"10079_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1600-6143.2004.00335.x","volume":"4","author":"G Morris-Stiff","year":"2004","unstructured":"Morris-Stiff, G., et al. (2004). Transmission of donor melanoma to multiple organ transplant recipients. American Journal of Transplantation, 4, 444\u2013446.","journal-title":"American Journal of Transplantation"},{"key":"10079_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/cas.13917","volume":"110","author":"H Endo","year":"2019","unstructured":"Endo, H., & Inoue, M. (2019). Dormancy in cancer. Cancer Science, 110, 474\u2013480.","journal-title":"Cancer Science"},{"key":"10079_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1084\/jem.136.2.261","volume":"136","author":"MA Gimbrone Jr","year":"1972","unstructured":"Gimbrone, M. A., Jr., Leapman, S. B., Cotran, R. S., & Folkman, J. (1972). Tumor dormancy in vivo by prevention of neovascularization. Journal of Experimental Medicine, 136, 261\u2013276.","journal-title":"Journal of Experimental Medicine"},{"key":"10079_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nm0295-149","volume":"1","author":"L Holmgren","year":"1995","unstructured":"Holmgren, L., O\u2019Reilly, M. S., & Folkman, J. (1995). Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine, 1, 149\u2013153.","journal-title":"Nature Medicine"},{"key":"10079_CR27","unstructured":"Stewart, T. H. (1996). Immune mechanisms and tumor dormancy. Medicina (B Aires), 56: (Suppl 1), 74\u201382."},{"key":"10079_CR28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41556-018-0214-0","volume":"20","author":"ET Goddard","year":"2018","unstructured":"Goddard, E. T., Bozic, I., Riddell, S. R., & Ghajar, C. M. (2018). Dormant tumour cells, their niches and the influence of immunity. Nature Cell Biology, 20, 1240\u20131249.","journal-title":"Nature Cell Biology"},{"key":"10079_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/bies.950140309","volume":"14","author":"D Rusciano","year":"1992","unstructured":"Rusciano, D., & Burger, M. M. (1992). Why do cancer cells metastasize into particular organs? BioEssays, 14, 185\u2013194.","journal-title":"BioEssays"},{"key":"10079_CR30","first-page":"175","volume":"948","author":"GL Nicolson","year":"1988","unstructured":"Nicolson, G. L. (1988). Cancer metastasis: Tumor cell and host organ properties important in metastasis to specific secondary sites. Biochimica et Biophysica Acta, 948, 175\u2013224.","journal-title":"Biochimica et Biophysica Acta"},{"key":"10079_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/BF00750584","volume":"412","author":"AH Graf","year":"1988","unstructured":"Graf, A. H., Buchberger, W., Langmayr, H., & Schmid, K. W. (1988). Site preference of metastatic tumours of the brain. Virchows Arch A Pathol Anat Histopathol, 412, 493\u2013498.","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10079_CR32","first-page":"98","volume":"8","author":"S Paget","year":"1989","unstructured":"Paget, S. (1989). The distribution of secondary growths in cancer of the breast 1889. Cancer Metastasis Rev, 8, 98\u2013101.","journal-title":"Cancer Metastasis Rev,"},{"key":"10079_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki, M., et al. (2014). Metastatic sites and survival in lung cancer. Lung Cancer, 86, 78\u201384.","journal-title":"Lung Cancer"},{"key":"10079_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10555-007-9072-0","volume":"26","author":"JE Talmadge","year":"2007","unstructured":"Talmadge, J. E., Donkor, M., & Scholar, E. (2007). Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer and Metastasis Reviews, 26, 373\u2013400.","journal-title":"Cancer and Metastasis Reviews"},{"key":"10079_CR35","first-page":"3584","volume":"44","author":"D Tarin","year":"1984","unstructured":"Tarin, D., et al. (1984). Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Research, 44, 3584\u20133592.","journal-title":"Cancer Research"},{"key":"10079_CR36","first-page":"773","volume":"45","author":"IJ Fidler","year":"1970","unstructured":"Fidler, I. J. (1970). Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2\u2032-deoxyuridine. Journal of the National Cancer Institute, 45, 773\u2013782.","journal-title":"Journal of the National Cancer Institute"},{"key":"10079_CR37","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","volume":"13","author":"S Riethdorf","year":"2007","unstructured":"Riethdorf, S., et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the cell search system. Clinical Cancer Research, 13, 920\u2013928.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/cancers13020268","volume":"13","author":"C Wang","year":"2021","unstructured":"Wang, C., et al. (2021). Improved prognostic stratification using circulating tumor cell clusters in patients with metastatic castration-resistant prostate cancer. Cancers (Basel), 13, 268.","journal-title":"Cancers (Basel)"},{"key":"10079_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc2627","volume":"9","author":"CA Klein","year":"2009","unstructured":"Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews Cancer, 9, 302\u2013312.","journal-title":"Nature Reviews Cancer"},{"key":"10079_CR40","first-page":"193","volume":"3","author":"L Weiss","year":"1983","unstructured":"Weiss, L. (1983). Random and nonrandom processes in metastasis, and metastatic inefficiency. Invasion and Metastasis, 3, 193\u2013207.","journal-title":"Invasion and Metastasis"},{"key":"10079_CR41","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/1097-0142(19921001)70:7<1928::AID-CNCR2820700720>3.0.CO;2-R","volume":"70","author":"C Arnerl\u00f6v","year":"1992","unstructured":"Arnerl\u00f6v, C., et al. (1992). Breast carcinoma growth rate described by mammographic doubling time and S-phase fraction Correlations to clinical and histopathologic factors in a screened population. Cancer, 70, 1928\u20131934.","journal-title":"Cancer"},{"key":"10079_CR42","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(02)09838-0","volume":"360","author":"CA Klein","year":"2002","unstructured":"Klein, C. A., et al. (2002). Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet, 360, 683\u2013689.","journal-title":"Lancet"},{"key":"10079_CR43","first-page":"2345","volume":"36","author":"IV Gruber","year":"2016","unstructured":"Gruber, I. V., et al. (2016). Relationship between hematogenous tumor cell dissemination and cellular immunity in DCIS patients. Anticancer Research, 36, 2345\u20132351.","journal-title":"Anticancer Research"},{"key":"10079_CR44","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1002\/ijc.25895","volume":"129","author":"N S\u00e4nger","year":"2011","unstructured":"S\u00e4nger, N., et al. (2011). Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. International Journal of Cancer, 129, 2522\u20132526.","journal-title":"International Journal of Cancer"},{"key":"10079_CR45","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1038\/s41467-020-16995-y","volume":"11","author":"Z Hu","year":"2020","unstructured":"Hu, Z., & Curtis, C. (2020). Looking backward in time to define the chronology of metastasis. Nature Communications, 11, 3213.","journal-title":"Nature Communications"},{"key":"10079_CR46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrc3820","volume":"14","author":"C Alix-Panabieres","year":"2014","unstructured":"Alix-Panabieres, C., & Pantel, K. (2014). Challenges in circulating tumour cell research. Nature Reviews Cancer, 14, 623\u2013631.","journal-title":"Nature Reviews Cancer"},{"key":"10079_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/1878-0261.12022","volume":"11","author":"A Dasgupta","year":"2017","unstructured":"Dasgupta, A., Lim, A. R., & Ghajar, C. M. (2017). Circulating and disseminated tumor cells: Harbingers or initiators of metastasis? Molecular Oncology, 11, 40\u201361.","journal-title":"Molecular Oncology"},{"key":"10079_CR48","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccr.2005.08.003","volume":"8","author":"JA Schardt","year":"2005","unstructured":"Schardt, J. A., et al. (2005). Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell, 8, 227\u2013239.","journal-title":"Cancer Cell"},{"key":"10079_CR49","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1073\/pnas.1331931100","volume":"100","author":"O Schmidt-Kittler","year":"2003","unstructured":"Schmidt-Kittler, O., et al. (2003). From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A, 100, 7737\u20137742.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10079_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S1535-6108(03)00167-3","volume":"4","author":"JW Gray","year":"2003","unstructured":"Gray, J. W. (2003). Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell, 4, 4\u20136.","journal-title":"Cancer Cell"},{"key":"10079_CR51","doi-asserted-by":"publisher","first-page":"15901","DOI":"10.1073\/pnas.2634067100","volume":"100","author":"B Weigelt","year":"2003","unstructured":"Weigelt, B. (2003). Gene expression profiles of primary breast tumors maintained in distant metastases. Proceedings of the National Academy of Sciences, 100, 15901\u201315905.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10079_CR52","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41575-019-0200-4","volume":"16","author":"A Magr\u00ec","year":"2019","unstructured":"Magr\u00ec, A., & Bardelli, A. (2019). Does early metastatic seeding occur in colorectal cancer? Nature Reviews. Gastroenterology & Hepatology, 16, 651\u2013653.","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10079_CR53","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1073\/pnas.0712345105","volume":"105","author":"S Jones","year":"2008","unstructured":"Jones, S., et al. (2008). Comparative lesion sequencing provides insights into tumor evolution. Proceeding National Academic Science U S A, 105, 4283\u20134288.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10079_CR54","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41588-019-0423-x","volume":"51","author":"Z Hu","year":"2019","unstructured":"Hu, Z., et al. (2019). Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 51, 1113\u20131122.","journal-title":"Nature Genetics"},{"key":"10079_CR55","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ccr.2008.04.005","volume":"13","author":"NH Stoecklein","year":"2008","unstructured":"Stoecklein, N. H., et al. (2008). Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell, 13, 441\u2013453.","journal-title":"Cancer Cell"},{"key":"10079_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ccell.2019.12.004","volume":"37","author":"NJ Birkbak","year":"2020","unstructured":"Birkbak, N. J., & McGranahan, N. (2020). Cancer genome evolutionary trajectories in metastasis. Cancer Cell, 37, 8\u201319.","journal-title":"Cancer Cell"},{"key":"10079_CR57","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.V61.3.600.600","volume":"61","author":"W Hocking","year":"1983","unstructured":"Hocking, W., Goodman, J., & Golde, D. (1983). Granulocytosis associated with tumor cell production of colony-stimulating activity. Blood, 61, 600\u2013603.","journal-title":"Blood"},{"key":"10079_CR58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjd.19059","volume":"183","author":"L Fredeau","year":"2020","unstructured":"Fredeau, L., et al. (2020). Paraneoplastic neutrophilic leukaemoid reaction in a patient with melanoma: Association between tumour volume and leucocytosis. British Journal of Dermatology, 183, 579\u2013580.","journal-title":"British Journal of Dermatology"},{"key":"10079_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero, C. M., et al. (2009). Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunology, Immunotherapy, 58, 49\u201359.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10079_CR60","doi-asserted-by":"publisher","first-page":"794","DOI":"10.4049\/jimmunol.1202088","volume":"190","author":"L Wang","year":"2013","unstructured":"Wang, L., et al. (2013). Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8\/A9 proinflammatory proteins. The Journal of Immunology, 190, 794\u2013804.","journal-title":"The Journal of Immunology"},{"key":"10079_CR61","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1158\/1078-0432.CCR-07-0182","volume":"13","author":"JE Talmadge","year":"2007","unstructured":"Talmadge, J. E. (2007). Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clinical Cancer Research, 13, 5243\u20135248.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR62","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1172\/JCI112988","volume":"79","author":"CA Sieff","year":"1987","unstructured":"Sieff, C. A. (1987). Hematopoietic growth factors. The Journal of Clinical Investigation, 79, 1549\u20131557.","journal-title":"The Journal of Clinical Investigation"},{"key":"10079_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1046\/j.1537-2995.1999.39199116893.x","volume":"39","author":"TA Lane","year":"1999","unstructured":"Lane, T. A., et al. (1999). Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion, 39, 39\u201347.","journal-title":"Transfusion"},{"key":"10079_CR64","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4049\/jimmunol.123.2.942","volume":"123","author":"S Slavin","year":"1979","unstructured":"Slavin, S., & Strober, S. (1979). Induction of allograft tolerance after total lymphoid irradiation (TLI): Development of suppressor cells of the mixed leukocyte reaction (MLR). The Journal of Immunology, 123, 942\u2013946.","journal-title":"The Journal of Immunology"},{"key":"10079_CR65","first-page":"95","volume":"1","author":"AS Pak","year":"1995","unstructured":"Pak, A. S., et al. (1995). Mechanisms of immune suppression in patients with head and neck cancer: Presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clinical Cancer Research, 1, 95\u2013103.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR66","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00262-012-1294-5","volume":"61","author":"CA Dumitru","year":"2012","unstructured":"Dumitru, C. A., Moses, K., Trellakis, S., Lang, S., & Brandau, S. (2012). Neutrophils and granulocytic myeloid-derived suppressor cells: Immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunology, Immunotherapy, 61, 1155\u20131167.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10079_CR67","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1158\/0008-5472.CAN-09-3767","volume":"70","author":"I Poschke","year":"2010","unstructured":"Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. (2010). Immature immunosuppressive CD14+HLA-DR-\/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Research, 70, 4335\u20134345.","journal-title":"Cancer Research"},{"key":"10079_CR68","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","volume":"69","author":"PC Rodriguez","year":"2009","unstructured":"Rodriguez, P. C., et al. (2009). Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Research, 69, 1553\u20131560.","journal-title":"Cancer Research"},{"key":"10079_CR69","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge, J. E., & Gabrilovich, D. I. (2013). History of myeloid-derived suppressor cells. Nature Reviews Cancer, 13, 739\u2013752.","journal-title":"Nature Reviews Cancer"},{"key":"10079_CR70","first-page":"4756","volume":"61","author":"J Schmielau","year":"2001","unstructured":"Schmielau, J., & Finn, O. J. (2001). Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Research, 61, 4756\u20134760.","journal-title":"Cancer Research"},{"key":"10079_CR71","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","volume":"182","author":"CA Corzo","year":"2009","unstructured":"Corzo, C. A., et al. (2009). Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. The Journal of Immunology, 182, 5693\u20135701.","journal-title":"The Journal of Immunology"},{"key":"10079_CR72","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-04-4505","volume":"65","author":"AH Zea","year":"2005","unstructured":"Zea, A. H., et al. (2005). Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Research, 65, 3044\u20133048.","journal-title":"Cancer Research"},{"key":"10079_CR73","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.intimp.2018.10.026","volume":"65","author":"S Khadge","year":"2018","unstructured":"Khadge, S., et al. (2018). Immune regulation and anti-cancer activity by lipid inflammatory mediators. International Immunopharmacology, 65, 580\u2013592.","journal-title":"International Immunopharmacology"},{"key":"10079_CR74","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1440-1681.2007.04638.x","volume":"34","author":"W Durante","year":"2007","unstructured":"Durante, W., Johnson, F. K., & Johnson, R. A. (2007). Arginase: A critical regulator of nitric oxide synthesis and vascular function. Clinical and Experimental Pharmacology and Physiology, 34, 906\u2013911.","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"key":"10079_CR75","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/s41467-019-10979-3","volume":"10","author":"M Czystowska-Kuzmicz","year":"2019","unstructured":"Czystowska-Kuzmicz, M., et al. (2019). Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nature Communications, 10, 3000.","journal-title":"Nature Communications"},{"key":"10079_CR76","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger, R., et al. (2016). L-arginine modulates t cell metabolism and enhances survival and anti-tumor activity. Cell, 167, 829-842.e813.","journal-title":"Cell"},{"key":"10079_CR77","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3109\/08820139.2012.680634","volume":"41","author":"P Raber","year":"2012","unstructured":"Raber, P., Ochoa, A. C., & Rodr\u00edguez, P. C. (2012). Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: Mechanisms of T cell suppression and therapeutic perspectives. Immunological Investigations, 41, 614\u2013634.","journal-title":"Immunological Investigations"},{"key":"10079_CR78","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","volume":"64","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez, P. C., et al. (2004). Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Research, 64, 5839\u20135849.","journal-title":"Cancer Research"},{"key":"10079_CR79","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","volume":"109","author":"PC Rodriguez","year":"2006","unstructured":"Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2006). l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood, 109, 1568\u20131573.","journal-title":"Blood"},{"key":"10079_CR80","doi-asserted-by":"publisher","first-page":"21123","DOI":"10.1074\/jbc.M110675200","volume":"277","author":"PC Rodriguez","year":"2002","unstructured":"Rodriguez, P. C., et al. (2002). Regulation of T cell receptor CD3zeta chain expression by L-arginine. Journal of Biological Chemistry, 277, 21123\u201321129.","journal-title":"Journal of Biological Chemistry"},{"key":"10079_CR81","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S1471-4906(03)00132-7","volume":"24","author":"V Bronte","year":"2003","unstructured":"Bronte, V., Serafini, P., Mazzoni, A., Segal, D. M., & Zanovello, P. (2003). L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends in Immunology, 24, 302\u2013306.","journal-title":"Trends in Immunology"},{"key":"10079_CR82","doi-asserted-by":"crossref","unstructured":"Eiserich, J. P. (2003). Nitric oxide: A simple free radical with complex chemistry and biology. In M. P. Schneider (ed.), Chemical Probes in Biology (pp. 1-19). \u00a9 2003 Kluwer Academic Publishers.","DOI":"10.1007\/978-94-007-0958-4_1"},{"key":"10079_CR83","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.4049\/jimmunol.1103553","volume":"188","author":"P Jayaraman","year":"2012","unstructured":"Jayaraman, P., et al. (2012). Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. The Journal of Immunology, 188, 5365\u20135376.","journal-title":"The Journal of Immunology"},{"key":"10079_CR84","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4049\/jimmunol.168.2.689","volume":"168","author":"A Mazzoni","year":"2002","unstructured":"Mazzoni, A., et al. (2002). Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. The Journal of Immunology, 168, 689\u2013695.","journal-title":"The Journal of Immunology"},{"key":"10079_CR85","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj, S., et al. (2007). Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nature Medicine, 13, 828\u2013835.","journal-title":"Nature Medicine"},{"key":"10079_CR86","doi-asserted-by":"publisher","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","volume":"172","author":"S Kusmartsev","year":"2004","unstructured":"Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004). Antigen-specific inhibition of CD8<sup>+<\/sup> T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. The Journal of Immunology, 172, 989\u2013999.","journal-title":"The Journal of Immunology"},{"key":"10079_CR87","doi-asserted-by":"publisher","first-page":"15424","DOI":"10.1038\/s41598-017-14970-0","volume":"7","author":"J Markowitz","year":"2017","unstructured":"Markowitz, J., et al. (2017). Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Scientific Reports, 7, 15424.","journal-title":"Scientific Reports"},{"key":"10079_CR88","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.4049\/jimmunol.0902661","volume":"184","author":"S Nagaraj","year":"2010","unstructured":"Nagaraj, S., Schrum, A. G., Cho, H.-I., Celis, E., & Gabrilovich, D. I. (2010). Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. The Journal of Immunology, 184, 3106\u20133116.","journal-title":"The Journal of Immunology"},{"key":"10079_CR89","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2051-1426-1-10","volume":"1","author":"R Wesolowski","year":"2013","unstructured":"Wesolowski, R., Markowitz, J., & Carson, W. E. (2013). Myeloid derived suppressor cells \u2013 a new therapeutic target in the treatment of cancer. Journal for ImmunoTherapy of Cancer, 1, 10.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10079_CR90","doi-asserted-by":"publisher","first-page":"10094","DOI":"10.1073\/pnas.1800695115","volume":"115","author":"S Feng","year":"2018","unstructured":"Feng, S., et al. (2018). Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. Proc Natl Acad Sci U S A, 115, 10094\u201310099.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10079_CR91","doi-asserted-by":"publisher","first-page":"200111","DOI":"10.1098\/rsob.200111","volume":"10","author":"MM Yaseen","year":"2020","unstructured":"Yaseen, M. M., Abuharfeil, N. M., Darmani, H., & Daoud, A. (2020). Mechanisms of immune suppression by myeloid-derived suppressor cells: The role of interleukin-10 as a key immunoregulatory cytokine. Open Biology, 10, 200111.","journal-title":"Open Biology"},{"key":"10079_CR92","first-page":"101","volume":"17","author":"JE Talmadge","year":"1996","unstructured":"Talmadge, J. E., et al. (1996). Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplantation, 17, 101\u2013109.","journal-title":"Bone Marrow Transplantation"},{"key":"10079_CR93","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nature06348","volume":"450","author":"F Shojaei","year":"2007","unstructured":"Shojaei, F., et al. (2007). Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature, 450, 825\u2013831.","journal-title":"Nature"},{"key":"10079_CR94","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan, R. N., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, 820\u2013827.","journal-title":"Nature"},{"key":"10079_CR95","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen, D. X., Bos, P. D., & Massague, J. (2009). Metastasis: From dissemination to organ-specific colonization. Nature Reviews Cancer, 9, 274\u2013284.","journal-title":"Nature Reviews Cancer"},{"key":"10079_CR96","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fcell.2015.00004","volume":"3","author":"A Jacob","year":"2015","unstructured":"Jacob, A., & Prekeris, R. (2015). The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol, 3, 4.","journal-title":"Front Cell Dev Biol"},{"key":"10079_CR97","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","volume":"23","author":"N Horikawa","year":"2017","unstructured":"Horikawa, N., et al. (2017). Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clinical Cancer Research, 23, 587\u2013599.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR98","doi-asserted-by":"publisher","first-page":"e998519","DOI":"10.1080\/2162402X.2014.998519","volume":"4","author":"S Karakhanova","year":"2015","unstructured":"Karakhanova, S., et al. (2015). Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Oncoimmunology, 4, e998519.","journal-title":"Oncoimmunology"},{"key":"10079_CR99","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MOH.0b013e3283477962","volume":"18","author":"J Hoggatt","year":"2011","unstructured":"Hoggatt, J., & Pelus, L. M. (2011). Many mechanisms mediating mobilization: An alliterative review. Current Opinion in Hematology, 18, 231\u2013238.","journal-title":"Current Opinion in Hematology"},{"key":"10079_CR100","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1172\/JCI15994","volume":"111","author":"JP Levesque","year":"2003","unstructured":"Levesque, J. P., Hendy, J., Takamatsu, Y., Simmons, P. J., & Bendall, L. J. (2003). Disruption of the CXCR4\/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. The Journal of Clinical Investigation, 111, 187\u2013196.","journal-title":"The Journal of Clinical Investigation"},{"key":"10079_CR101","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s10156-007-0553-4","volume":"13","author":"T Saito","year":"2007","unstructured":"Saito, T., et al. (2007). Elevated serum levels of human matrix metalloproteinase-9 (MMP-9) during the induction of peripheral blood stem cell mobilization by granulocyte colony-stimulating factor (G-CSF). Journal of Infection and Chemotherapy, 13, 426\u2013428.","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10079_CR102","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1182\/blood-2004-08-3238","volume":"105","author":"M Xu","year":"2005","unstructured":"Xu, M., et al. (2005). Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood, 105, 4508\u20134515.","journal-title":"Blood"},{"key":"10079_CR103","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0092-8674(02)00754-7","volume":"109","author":"B Heissig","year":"2002","unstructured":"Heissig, B., et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109, 625\u2013637.","journal-title":"Cell"},{"key":"10079_CR104","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/carcin\/20.5.749","volume":"20","author":"ZS Zeng","year":"1999","unstructured":"Zeng, Z. S., Cohen, A. M., & Guillem, J. G. (1999). Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis, 20, 749\u2013755.","journal-title":"Carcinogenesis"},{"key":"10079_CR105","first-page":"5365","volume":"53","author":"B Davies","year":"1993","unstructured":"Davies, B., et al. (1993). Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Research, 53, 5365\u20135369.","journal-title":"Cancer Research"},{"key":"10079_CR106","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/bjc.1994.30","volume":"69","author":"FC Hamdy","year":"1994","unstructured":"Hamdy, F. C., et al. (1994). Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. British Journal of Cancer, 69, 177\u2013182.","journal-title":"British Journal of Cancer"},{"key":"10079_CR107","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1073\/pnas.1113744109","volume":"109","author":"V Cortez-Retamozo","year":"2012","unstructured":"Cortez-Retamozo, V., et al. (2012). Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A, 109, 2491\u20132496.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10079_CR108","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1172\/JCI97973","volume":"128","author":"C Wu","year":"2018","unstructured":"Wu, C., et al. (2018). Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. The Journal of Clinical Investigation, 128, 3425\u20133438.","journal-title":"The Journal of Clinical Investigation"},{"key":"10079_CR109","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/1097-0142(19870701)60:1<100::AID-CNCR2820600118>3.0.CO;2-9","volume":"60","author":"B Klein","year":"1987","unstructured":"Klein, B., et al. (1987). Splenomegaly and solitary spleen metastasis in solid tumors. Cancer, 60, 100\u2013102.","journal-title":"Cancer"},{"key":"10079_CR110","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/1097-0142(196911)24:5<1041::AID-CNCR2820240526>3.0.CO;2-C","volume":"24","author":"JM Kiely","year":"1969","unstructured":"Kiely, J. M., & Silverstein, M. N. (1969). Metastatic carcinoma simulating agnogenic myeloid metaplasia and myelofibrosis. Cancer, 24, 1041\u20131044.","journal-title":"Cancer"},{"key":"10079_CR111","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/hep.1840210314","volume":"21","author":"HJ Schlitt","year":"1995","unstructured":"Schlitt, H. J., et al. (1995). Extramedullary erythropoiesis in human liver grafts. Hepatology, 21, 689\u2013696.","journal-title":"Hepatology"},{"key":"10079_CR112","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1365-2559.2004.01970.x","volume":"45","author":"CEH Craig","year":"2004","unstructured":"Craig, C. E. H., Quaglia, A., & Dhillon, A. P. (2004). Extramedullary haematopoiesis in massive hepatic necrosis. Histopathology, 45, 518\u2013525.","journal-title":"Histopathology"},{"key":"10079_CR113","first-page":"9515404","volume":"2016","author":"GR Mohyuddin","year":"2016","unstructured":"Mohyuddin, G. R., & Yacoub, A. (2016). Primary myelofibrosis presenting as extramedullary hematopoiesis in a transplanted liver graft: Case report and review of the literature. Case Rep Hematol, 2016, 9515404.","journal-title":"Case Rep Hematol"},{"key":"10079_CR114","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/mpo.2950130210","volume":"13","author":"T Yablonski-Peretz","year":"1985","unstructured":"Yablonski-Peretz, T., et al. (1985). Secondary myelofibrosis with metastatic breast cancer simulating agnogenic myeloid metaplasia: Report of a case and review of the literature. Medical and Pediatric Oncology, 13, 92\u201396.","journal-title":"Medical and Pediatric Oncology"},{"key":"10079_CR115","doi-asserted-by":"publisher","first-page":"L434","DOI":"10.1152\/ajplung.00156.2019","volume":"317","author":"AC Oliveira","year":"2019","unstructured":"Oliveira, A. C., et al. (2019). Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia. American Journal of Physiology. Lung Cellular and Molecular Physiology, 317, L434\u2013L444.","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10079_CR116","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4049\/jimmunol.1701019","volume":"200","author":"S Ostrand-Rosenberg","year":"2018","unstructured":"Ostrand-Rosenberg, S., & Fenselau, C. (2018). Myeloid-derived suppressor cells: Immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. The Journal of Immunology, 200, 422\u2013431.","journal-title":"The Journal of Immunology"},{"key":"10079_CR117","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1165\/rcmb.2017-0214OC","volume":"58","author":"AJ Bryant","year":"2018","unstructured":"Bryant, A. J., et al. (2018). Myeloid-derived suppressor cells are necessary for development of pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 58, 170\u2013180.","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10079_CR118","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H., et al. (2017). 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. New England Journal of Medicine, 377, 1836\u20131846.","journal-title":"New England Journal of Medicine"},{"key":"10079_CR119","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. New England Journal of Medicine, 285, 1182\u20131186.","journal-title":"New England Journal of Medicine"},{"key":"10079_CR120","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353\u2013364.","journal-title":"Cell"},{"key":"10079_CR121","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pharmthera.2015.06.006","volume":"153","author":"DW Siemann","year":"2015","unstructured":"Siemann, D. W., & Horsman, M. R. (2015). Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacology & Therapeutics, 153, 107\u2013124.","journal-title":"Pharmacology & Therapeutics"},{"key":"10079_CR122","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.2174\/09298673113209990250","volume":"20","author":"M Retsky","year":"2013","unstructured":"Retsky, M., et al. (2013). Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: New findings and a review. Current Medicinal Chemistry, 20, 4163\u20134176.","journal-title":"Current Medicinal Chemistry"},{"key":"10079_CR123","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.4049\/jimmunol.162.5.2842","volume":"162","author":"JD Farrar","year":"1999","unstructured":"Farrar, J. D., et al. (1999). Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol, 162, 2842\u20132849.","journal-title":"J Immunol"},{"key":"10079_CR124","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21, 137\u2013148.","journal-title":"Immunity"},{"key":"10079_CR125","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0065-230X(08)60240-7","volume":"34","author":"EF Wheelock","year":"1981","unstructured":"Wheelock, E. F., Weinhold, K. J., & Levich, J. (1981). The tumor dormant state. Advances in Cancer Research, 34, 107\u2013140.","journal-title":"Advances in Cancer Research"},{"key":"10079_CR126","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","volume":"450","author":"CM Koebel","year":"2007","unstructured":"Koebel, C. M., et al. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450, 903\u2013907.","journal-title":"Nature"},{"key":"10079_CR127","first-page":"5155","volume":"47","author":"YA Sidky","year":"1987","unstructured":"Sidky, Y. A., & Borden, E. C. (1987). Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. Cancer Research, 47, 5155\u20135161.","journal-title":"Cancer Research"},{"key":"10079_CR128","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jnci\/87.8.581","volume":"87","author":"EE Voest","year":"1995","unstructured":"Voest, E. E., et al. (1995). Inhibition of angiogenesis in vivo by interleukin 12. Journal of the National Cancer Institute, 87, 581\u2013586.","journal-title":"Journal of the National Cancer Institute"},{"key":"10079_CR129","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10555-012-9373-9","volume":"31","author":"JP Sleeman","year":"2012","unstructured":"Sleeman, J. P. (2012). The metastatic niche and stromal progression. Cancer and Metastasis Reviews, 31, 429\u2013440.","journal-title":"Cancer and Metastasis Reviews"},{"key":"10079_CR130","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","volume":"20","author":"M Fane","year":"2020","unstructured":"Fane, M., & Weeraratna, A. T. (2020). How the ageing microenvironment influences tumour progression. Nature Reviews Cancer, 20, 89\u2013106.","journal-title":"Nature Reviews Cancer"},{"key":"10079_CR131","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/bonekey.2015.32","volume":"4","author":"N Baschuk","year":"2015","unstructured":"Baschuk, N., Rautela, J., & Parker, B. S. (2015). Bone specific immunity and its impact on metastasis. Bonekey Rep, 4, 665.","journal-title":"Bonekey Rep"},{"key":"10079_CR132","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/jnci\/82.24.1890","volume":"82","author":"M Nakajima","year":"1990","unstructured":"Nakajima, M., Morikawa, K., Fabra, A., Bucana, C. D., & Fidler, I. J. (1990). Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. Journal of the National Cancer Institute, 82, 1890\u20131898.","journal-title":"Journal of the National Cancer Institute"},{"key":"10079_CR133","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mce.2009.07.004","volume":"310","author":"S Casimiro","year":"2009","unstructured":"Casimiro, S., Guise, T. A., & Chirgwin, J. (2009). The critical role of the bone microenvironment in cancer metastases. Molecular and Cellular Endocrinology, 310, 71\u201381.","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10079_CR134","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10555-013-9420-1","volume":"32","author":"J Sceneay","year":"2013","unstructured":"Sceneay, J., Smyth, M. J., & M\u00f6ller, A. (2013). The pre-metastatic niche: Finding common ground. Cancer and Metastasis Reviews, 32, 449\u2013464.","journal-title":"Cancer and Metastasis Reviews"},{"key":"10079_CR135","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013). The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology, 138, 105\u2013115.","journal-title":"Immunology"},{"key":"10079_CR136","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1196\/annals.1392.021","volume":"1106","author":"A Wilson","year":"2007","unstructured":"Wilson, A., et al. (2007). Dormant and self-renewing hematopoietic stem cells and their niches. Annals of the New York Academy of Sciences, 1106, 64\u201375.","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10079_CR137","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.2174\/138161210794455003","volume":"16","author":"S Liekens","year":"2010","unstructured":"Liekens, S., Schols, D., & Hatse, S. (2010). CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Current Pharmaceutical Design, 16, 3903\u20133920.","journal-title":"Current Pharmaceutical Design"},{"key":"10079_CR138","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","volume":"25","author":"T Sugiyama","year":"2006","unstructured":"Sugiyama, T., Kohara, H., Noda, M., & Nagasawa, T. (2006). Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity, 25, 977\u2013988.","journal-title":"Immunity"},{"key":"10079_CR139","doi-asserted-by":"publisher","first-page":"340ra","DOI":"10.1126\/scitranslmed.aad4059","volume":"8","author":"TT Price","year":"2016","unstructured":"Price, T. T., et al. (2016). Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci Transl Med, 8, 340ra\u201334373.","journal-title":"Sci Transl Med"},{"key":"10079_CR140","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1126\/science.aao4227","volume":"361","author":"J Albrengues","year":"2018","unstructured":"Albrengues, J., et al. (2018). Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science, 361, 6409.","journal-title":"Science"},{"key":"10079_CR141","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1083\/jcb.147.1.89","volume":"147","author":"JA Aguirre Ghiso","year":"1999","unstructured":"Aguirre Ghiso, J. A., Kovalski, K., & Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol, 147, 89\u2013104.","journal-title":"J Cell Biol"},{"key":"10079_CR142","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1172\/JCI43414","volume":"121","author":"Y Shiozawa","year":"2011","unstructured":"Shiozawa, Y., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation, 121, 1298\u20131312.","journal-title":"The Journal of Clinical Investigation"},{"key":"10079_CR143","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2141.1994.tb03271.x","volume":"86","author":"AJ Vora","year":"1994","unstructured":"Vora, A. J., Toh, C. H., Peel, J., & Greaves, M. (1994). Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: Risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. British Journal of Haematology, 86, 180\u2013182.","journal-title":"British Journal of Haematology"},{"key":"10079_CR144","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1084\/jem.20072513","volume":"205","author":"Y Nie","year":"2008","unstructured":"Nie, Y., Han, Y. C., & Zou, Y. R. (2008). CXCR4 is required for the quiescence of primitive hematopoietic cells. Journal of Experimental Medicine, 205, 777\u2013783.","journal-title":"Journal of Experimental Medicine"},{"key":"10079_CR145","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1038\/sj.onc.1210429","volume":"26","author":"NP McCabe","year":"2007","unstructured":"McCabe, N. P., De, S., Vasanji, A., Brainard, J., & Byzova, T. V. (2007). Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene, 26, 6238\u20136243.","journal-title":"Oncogene"},{"key":"10079_CR146","first-page":"1832","volume":"62","author":"RS Taichman","year":"2002","unstructured":"Taichman, R. S., et al. (2002). Use of the stromal cell-derived factor-1\/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research, 62, 1832\u20131837.","journal-title":"Cancer Research"},{"key":"10079_CR147","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/35065016","volume":"410","author":"A Muller","year":"2001","unstructured":"Muller, A., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50\u201356.","journal-title":"Nature"},{"key":"10079_CR148","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1182\/blood-2012-12-475483","volume":"121","author":"B Boyerinas","year":"2013","unstructured":"Boyerinas, B., et al. (2013). Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood, 121, 4821\u20134831.","journal-title":"Blood"},{"key":"10079_CR149","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1089\/scd.2009.0445","volume":"19","author":"RS Taichman","year":"2010","unstructured":"Taichman, R. S., et al. (2010). Prospective identification and skeletal localization of cells capable of multilineage differentiation in vivo. Stem Cells Dev, 19, 1557\u20131570.","journal-title":"Stem Cells Dev"},{"key":"10079_CR150","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0962-8924(99)01559-7","volume":"9","author":"AD Whetton","year":"1999","unstructured":"Whetton, A. D., & Graham, G. J. (1999). Homing and mobilization in the stem cell niche. Trends in Cell Biology, 9, 233\u2013238.","journal-title":"Trends in Cell Biology"},{"key":"10079_CR151","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.exphem.2010.11.007","volume":"39","author":"Y Jung","year":"2011","unstructured":"Jung, Y., et al. (2011). Annexin-2 is a regulator of stromal cell-derived factor-1\/CXCL12 function in the hematopoietic stem cell endosteal niche. Experimental Hematology, 39, 151-166.e151.","journal-title":"Experimental Hematology"},{"key":"10079_CR152","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1158\/1541-7786.MCR-14-0118","volume":"13","author":"Y Jung","year":"2015","unstructured":"Jung, Y., et al. (2015). Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Molecular Cancer Research, 13, 197\u2013207.","journal-title":"Molecular Cancer Research"},{"key":"10079_CR153","doi-asserted-by":"publisher","first-page":"e27690","DOI":"10.1371\/journal.pone.0027690","volume":"6","author":"JD Waight","year":"2011","unstructured":"Waight, J. D., Hu, Q., Miller, A., Liu, S., & Abrams, S. I. (2011). Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One, 6, e27690.","journal-title":"PLoS One"},{"key":"10079_CR154","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.copbio.2016.02.002","volume":"40","author":"EE van der Toom","year":"2016","unstructured":"van der Toom, E. E., Verdone, J. E., & Pienta, K. J. (2016). Disseminated tumor cells and dormancy in prostate cancer metastasis. Current Opinion in Biotechnology, 40, 9\u201315.","journal-title":"Current Opinion in Biotechnology"},{"key":"10079_CR155","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/bjc.2013.822","volume":"110","author":"KT Morris","year":"2014","unstructured":"Morris, K. T., et al. (2014). G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. British Journal of Cancer, 110, 1211\u20131220.","journal-title":"British Journal of Cancer"},{"key":"10079_CR156","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1515\/CCLM.2007.025","volume":"45","author":"M Groblewska","year":"2007","unstructured":"Groblewska, M., et al. (2007). Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clinical Chemistry and Laboratory Medicine, 45, 30\u201334.","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"10079_CR157","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12967-015-0410-7","volume":"13","author":"LY OuYang","year":"2015","unstructured":"OuYang, L. Y., et al. (2015). Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. Journal of Translational Medicine, 13, 47.","journal-title":"Journal of Translational Medicine"},{"key":"10079_CR158","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1158\/0008-5472.CAN-10-0706","volume":"70","author":"HH Yan","year":"2010","unstructured":"Yan, H. H., et al. (2010). Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Research, 70, 6139\u20136149.","journal-title":"Cancer Research"},{"key":"10079_CR159","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/ijc.30538","volume":"140","author":"H Shi","year":"2017","unstructured":"Shi, H., et al. (2017). Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression. International Journal of Cancer, 140, 1370\u20131383.","journal-title":"International Journal of Cancer"},{"key":"10079_CR160","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1158\/0008-5472.CAN-10-1040","volume":"70","author":"JE Talmadge","year":"2010","unstructured":"Talmadge, J. E., & Fidler, I. J. (2010). AACR centennial series: The biology of cancer metastasis: Historical perspective. Cancer Research, 70, 5649\u20135669.","journal-title":"Cancer Research"},{"key":"10079_CR161","doi-asserted-by":"crossref","unstructured":"Mitchell, K. G., et al. (2020) Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: A descriptive analysis of a prospectively immunoprofiled cohort.\u00a0Journal for Immunotherapy of Cancer, 8, e000405","DOI":"10.1136\/jitc-2019-000405"},{"key":"10079_CR162","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/ajcp\/40.1.58","volume":"40","author":"JH Marymont Jr","year":"1963","unstructured":"Marymont, J. H., Jr., & Gross, S. (1963). Patterns of metastatic cancer in the spleen. American Journal of Clinical Pathology, 40, 58\u201366.","journal-title":"American Journal of Clinical Pathology"},{"key":"10079_CR163","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00432-008-0502-3","volume":"135","author":"J Sauer","year":"2009","unstructured":"Sauer, J., Sobolewski, K., & Dommisch, K. (2009). Splenic metastases\u2013not a frequent problem, but an underestimate location of metastases: Epidemiology and course. Journal of Cancer Research and Clinical Oncology, 135, 667\u2013671.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10079_CR164","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1126\/science.106.2754.348","volume":"106","author":"GF Watson","year":"1947","unstructured":"Watson, G. F., Diller, I. C., & Ludwick, N. V. (1947). Spleen extract and tumor growth. Science, 106, 348.","journal-title":"Science"},{"key":"10079_CR165","doi-asserted-by":"publisher","first-page":"106655","DOI":"10.1016\/j.intimp.2020.106655","volume":"85","author":"KE Cole","year":"2020","unstructured":"Cole, K. E., et al. (2020). Comparative phenotypes of peripheral blood and spleen cells from cancer patients. International Immunopharmacology, 85, 106655.","journal-title":"International Immunopharmacology"},{"key":"10079_CR166","doi-asserted-by":"publisher","first-page":"108628","DOI":"10.1016\/j.intimp.2022.108628","volume":"106","author":"KE Cole","year":"2022","unstructured":"Cole, K. E., et al. (2022). Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. International Immunopharmacology, 106, 108628.","journal-title":"International Immunopharmacology"},{"key":"10079_CR167","doi-asserted-by":"crossref","unstructured":"Peereboom, D. M., et al. (2019). Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight, 4, e130748","DOI":"10.1172\/jci.insight.130748"},{"key":"10079_CR168","doi-asserted-by":"publisher","first-page":"e954829","DOI":"10.4161\/21624011.2014.954829","volume":"4","author":"O Draghiciu","year":"2015","unstructured":"Draghiciu, O., Lubbers, J., Nijman, H. W., & Daemen, T. (2015). Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology, 4, e954829.","journal-title":"Oncoimmunology"},{"key":"10079_CR169","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber, R., et al. (2018). Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Frontiers in Immunology, 9, 1310.","journal-title":"Frontiers in Immunology"},{"key":"10079_CR170","doi-asserted-by":"crossref","unstructured":"Sun, L., et al. (2019). Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight, 4, e126853","DOI":"10.1172\/jci.insight.126853"},{"key":"10079_CR171","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","volume":"36","author":"TC Mitchell","year":"2018","unstructured":"Mitchell, T. C., et al. (2018). Epacadostat plus pembrolizumab in patients with advanced solid tumors: Phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037). Journal of Clinical Oncology, 36, 3223\u20133230.","journal-title":"Journal of Clinical Oncology"},{"key":"10079_CR172","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12967-016-1037-z","volume":"14","author":"E Eriksson","year":"2016","unstructured":"Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., & Ullenhag, G. (2016). Gemcitabine reduces MDSCs, tregs and TGF\u03b2-1 while restoring the teff\/treg ratio in patients with pancreatic cancer. Journal of Translational Medicine, 14, 282.","journal-title":"Journal of Translational Medicine"},{"key":"10079_CR173","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jim.2012.04.004","volume":"381","author":"A Kotsakis","year":"2012","unstructured":"Kotsakis, A., et al. (2012). Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. Journal of Immunological Methods, 381, 14\u201322.","journal-title":"Journal of Immunological Methods"},{"key":"10079_CR174","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/1753425912463618","volume":"19","author":"S Trellakis","year":"2013","unstructured":"Trellakis, S., et al. (2013). Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immunity, 19, 328\u2013336.","journal-title":"Innate Immunity"},{"key":"10079_CR175","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00262-013-1502-y","volume":"63","author":"NE Annels","year":"2014","unstructured":"Annels, N. E., et al. (2014). The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunology, Immunotherapy, 63, 175\u2013183.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10079_CR176","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","volume":"76","author":"E Limagne","year":"2016","unstructured":"Limagne, E., et al. (2016). Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX\u2013bevacizumab drug treatment regimen. Cancer Research, 76, 5241\u20135252.","journal-title":"Cancer Research"},{"key":"10079_CR177","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-14-0657","volume":"74","author":"J Kanterman","year":"2014","unstructured":"Kanterman, J., et al. (2014). Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Research, 74, 6022\u20136035.","journal-title":"Cancer Research"},{"key":"10079_CR178","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford, J., Dale, D. C., & Lyman, G. H. (2004). Chemotherapy-induced neutropenia. Cancer, 100, 228\u2013237.","journal-title":"Cancer"},{"key":"10079_CR179","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1007\/s00520-020-05603-w","volume":"28","author":"X Li","year":"2020","unstructured":"Li, X., et al. (2020). Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis. Supportive Care in Cancer, 28, 5085\u20135097.","journal-title":"Supportive Care in Cancer"},{"key":"10079_CR180","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00262-017-2038-3","volume":"66","author":"R Wesolowski","year":"2017","unstructured":"Wesolowski, R., et al. (2017). Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology, Immunotherapy, 66, 1437\u20131447.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10079_CR181","doi-asserted-by":"publisher","first-page":"103160","DOI":"10.1016\/j.ebiom.2020.103160","volume":"64","author":"F Dammeijer","year":"2021","unstructured":"Dammeijer, F., et al. (2021). Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response. EBioMedicine, 64, 103160.","journal-title":"EBioMedicine"},{"key":"10079_CR182","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/014860710102500123","volume":"25","author":"JB Ochoa","year":"2001","unstructured":"Ochoa, J. B., et al. (2001). Effects of L-arginine on the proliferation of T lymphocyte subpopulations. JPEN. Journal of Parenteral and Enteral Nutrition, 25, 23\u201329.","journal-title":"JPEN. Journal of Parenteral and Enteral Nutrition"},{"key":"10079_CR183","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1084\/jem.20050715","volume":"202","author":"PC Rodriguez","year":"2005","unstructured":"Rodriguez, P. C., et al. (2005). Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. Journal of Experimental Medicine, 202, 931\u2013939.","journal-title":"Journal of Experimental Medicine"},{"key":"10079_CR184","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1158\/0008-5472.CAN-06-4174","volume":"67","author":"P Sinha","year":"2007","unstructured":"Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Research, 67, 4507\u20134513.","journal-title":"Cancer Research"},{"key":"10079_CR185","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1189\/jlb.5VMR1116-458RRR","volume":"102","author":"JA Chesney","year":"2017","unstructured":"Chesney, J. A., Mitchell, R. A., & Yaddanapudi, K. (2017). Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. Journal of Leukocyte Biology, 102, 727\u2013740.","journal-title":"Journal of Leukocyte Biology"},{"key":"10079_CR186","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.intimp.2006.09.021","volume":"7","author":"JE Talmadge","year":"2007","unstructured":"Talmadge, J. E., et al. (2007). Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. International Immunopharmacology, 7, 140\u2013151.","journal-title":"International Immunopharmacology"},{"key":"10079_CR187","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/ph15070827","volume":"15","author":"AA El-Malah","year":"2022","unstructured":"El-Malah, A. A., et al. (2022). Selective COX-2 inhibitors: Road from success to controversy and the quest for repurposing. Pharmaceuticals (Basel), 15, 827.","journal-title":"Pharmaceuticals (Basel)"},{"key":"10079_CR188","doi-asserted-by":"publisher","first-page":"37","DOI":"10.15537\/smj.2022.43.1.20210574","volume":"43","author":"TM Mostafa","year":"2022","unstructured":"Mostafa, T. M., Alm El-Din, M. A., & Rashdan, A. R. (2022). Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer: A randomized controlled clinical study. Saudi Medicine Journal, 43, 37\u201344.","journal-title":"Saudi Medicine Journal"},{"key":"10079_CR189","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-14-1716","volume":"21","author":"JA Califano","year":"2015","unstructured":"Califano, J. A., et al. (2015). Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clinical Cancer Research, 21, 30\u201338.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR190","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","volume":"203","author":"P Serafini","year":"2006","unstructured":"Serafini, P., et al. (2006). Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Journal of Experimental Medicine, 203, 2691\u20132702.","journal-title":"Journal of Experimental Medicine"},{"key":"10079_CR191","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/2326-6066.CIR-13-0213","volume":"2","author":"KA Noonan","year":"2014","unstructured":"Noonan, K. A., Ghosh, N., Rudraraju, L., Bui, M., & Borrello, I. (2014). Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunology Research, 2, 725\u2013731.","journal-title":"Cancer Immunology Research"},{"key":"10079_CR192","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.4049\/jimmunol.177.7.4763","volume":"177","author":"AV Ezernitchi","year":"2006","unstructured":"Ezernitchi, A. V., et al. (2006). TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. The Journal of Immunology, 177, 4763\u20134772.","journal-title":"The Journal of Immunology"},{"key":"10079_CR193","doi-asserted-by":"publisher","first-page":"e1326440","DOI":"10.1080\/2162402X.2017.1326440","volume":"6","author":"JC Hassel","year":"2017","unstructured":"Hassel, J. C., et al. (2017). Tadalafil has biologic activity in human melanoma. Results of a pilot trial with tadalafil in patients with metastatic melanoma (TaMe). Oncoimmunology, 6, e1326440.","journal-title":"Oncoimmunology"},{"key":"10079_CR194","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","volume":"21","author":"DT Weed","year":"2015","unstructured":"Weed, D. T., et al. (2015). Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clinical Cancer Research, 21, 39\u201348.","journal-title":"Clinical Cancer Research"},{"issue":"57","key":"10079_CR195","first-page":"e51","volume":"40","author":"KT Danley","year":"2022","unstructured":"Danley, K. T., et al. (2022). The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy. Urol Oncol, 40(57), e51-57.","journal-title":"Urol Oncol"},{"key":"10079_CR196","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/ijc.27410","volume":"131","author":"I Poschke","year":"2012","unstructured":"Poschke, I., De Boniface, J., Mao, Y., & Kiessling, R. (2012). Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients. International Journal of Cancer, 131, 1611\u20131620.","journal-title":"International Journal of Cancer"},{"key":"10079_CR197","doi-asserted-by":"publisher","first-page":"8696923","DOI":"10.1155\/2018\/8696923","volume":"2018","author":"N Avtandilyan","year":"2018","unstructured":"Avtandilyan, N., Javrushyan, H., Petrosyan, G., & Trchounian, A. (2018). The involvement of arginase and nitric oxide synthase in breast cancer development: Arginase and NO synthase as therapeutic targets in cancer. BioMed Research International, 2018, 8696923.","journal-title":"BioMed Research International"},{"key":"10079_CR198","doi-asserted-by":"publisher","first-page":"152383","DOI":"10.1016\/j.prp.2019.03.012","volume":"215","author":"Z Ma","year":"2019","unstructured":"Ma, Z., et al. (2019). Overexpression of arginase-1 is an indicator of poor prognosis in patients with colorectal cancer. Pathology, Research and Practice, 215, 152383.","journal-title":"Pathology, Research and Practice"},{"key":"10079_CR199","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3389\/fimmu.2020.00938","volume":"11","author":"TM Grzywa","year":"2020","unstructured":"Grzywa, T. M., et al. (2020). Myeloid cell-derived arginase in cancer immune response. Frontiers in Immunology, 11, 938.","journal-title":"Frontiers in Immunology"},{"key":"10079_CR200","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/cei.12567","volume":"180","author":"A Gey","year":"2015","unstructured":"Gey, A., et al. (2015). Granulocytic myeloid-derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patients. Clinical and Experimental Immunology, 180, 280\u2013288.","journal-title":"Clinical and Experimental Immunology"},{"key":"10079_CR201","doi-asserted-by":"crossref","unstructured":"Lemberg, K. M., Gori, S. S., Tsukamoto, T., Rais, R., & Slusher, B. S. (2022). Clinical development of metabolic inhibitors for oncology. Journal Clinical Investigacion, 132,\u00a0e148550","DOI":"10.1172\/JCI148550"},{"key":"10079_CR202","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","volume":"5","author":"SM Steggerda","year":"2017","unstructured":"Steggerda, S. M., et al. (2017). Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. Journal for Immunotherapy of Cancer, 5, 101.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10079_CR203","doi-asserted-by":"publisher","first-page":"v160","DOI":"10.1093\/annonc\/mdz244.002","volume":"30","author":"A Naing","year":"2019","unstructured":"Naing, A., et al. (2019). Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced\/metastatic (adv\/met) solid tumours. Annals of Oncology, 30, v160.","journal-title":"Annals of Oncology"},{"key":"10079_CR204","doi-asserted-by":"publisher","first-page":"112840","DOI":"10.1016\/j.biopha.2022.112840","volume":"149","author":"F Niu","year":"2022","unstructured":"Niu, F., et al. (2022). Arginase: An emerging and promising therapeutic target for cancer treatment. Biomedicine & Pharmacotherapy, 149, 112840.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10079_CR205","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3389\/fimmu.2018.01684","volume":"9","author":"M Fauskanger","year":"2018","unstructured":"Fauskanger, M., Haabeth, O. A. W., Skjeldal, F. M., Bogen, B., & Tveita, A. A. (2018). Tumor killing by CD4(+) T cells is mediated via induction of inducible nitric oxide synthase-dependent macrophage cytotoxicity. Frontiers in Immunology, 9, 1684.","journal-title":"Frontiers in Immunology"},{"key":"10079_CR206","doi-asserted-by":"publisher","first-page":"eabj5070","DOI":"10.1126\/scitranslmed.abj5070","volume":"13","author":"AW Chung","year":"2021","unstructured":"Chung, A. W., et al. (2021). A phase 1\/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Science Translation Medicine, 13, eabj5070.","journal-title":"Science Translation Medicine"},{"key":"10079_CR207","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0731-7085(03)00531-4","volume":"35","author":"M Carini","year":"2004","unstructured":"Carini, M., et al. (2004). Chemiluminescence and LC\u2013MS\/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, 35, 277\u2013287.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10079_CR208","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/emm.2004.42","volume":"36","author":"K Chang","year":"2004","unstructured":"Chang, K., et al. (2004). Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of IkappaB. Experimental & Molecular Medicine, 36, 311\u2013324.","journal-title":"Experimental & Molecular Medicine"},{"key":"10079_CR209","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1073\/pnas.0409783102","volume":"102","author":"C De Santo","year":"2005","unstructured":"De Santo, C., et al. (2005). Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A, 102, 4185\u20134190.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10079_CR210","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jacc.2004.03.079","volume":"44","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci, S., et al. (2004). Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. Journal of the American College of Cardiology, 44, 635\u2013641.","journal-title":"Journal of the American College of Cardiology"},{"key":"10079_CR211","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s13238-015-0237-2","volume":"7","author":"W Li","year":"2016","unstructured":"Li, W., et al. (2016). G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers. Protein & Cell, 7, 130\u2013140.","journal-title":"Protein & Cell"},{"key":"10079_CR212","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile, M. A., et al. (2017). Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Journal for Immunotherapy of Cancer, 5, 53.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10079_CR213","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1182\/blood-2018-03-838946","volume":"133","author":"DKt Edwards","year":"2019","unstructured":"Edwards, DKt., et al. (2019). CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood, 133, 588\u2013599.","journal-title":"Blood"},{"key":"10079_CR214","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s40425-019-0674-1","volume":"7","author":"MC Apodaca","year":"2019","unstructured":"Apodaca, M. C., et al. (2019). Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells. Journal for Immunotherapy of Cancer, 7, 230.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10079_CR215","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","volume":"99","author":"N Tsukada","year":"2002","unstructured":"Tsukada, N., Burger, J. A., Zvaifler, N. J., & Kipps, T. J. (2002). Distinctive features of \u201cnurselike\u201d cells that differentiate in the context of chronic lymphocytic leukemia. Blood, 99, 1030\u20131037.","journal-title":"Blood"},{"key":"10079_CR216","doi-asserted-by":"publisher","first-page":"24576","DOI":"10.18632\/oncotarget.25191","volume":"9","author":"VD Edwards","year":"2018","unstructured":"Edwards, V. D., et al. (2018). Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget, 9, 24576\u201324589.","journal-title":"Oncotarget"},{"key":"10079_CR217","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1128\/CMR.10.4.742","volume":"10","author":"JH Curfs","year":"1997","unstructured":"Curfs, J. H., Meis, J. F., & Hoogkamp-Korstanje, J. A. (1997). A primer on cytokines: Sources, receptors, effects, and inducers. Clinical Microbiology Reviews, 10, 742\u2013780.","journal-title":"Clinical Microbiology Reviews"},{"key":"10079_CR218","doi-asserted-by":"publisher","first-page":"175883591985423","DOI":"10.1177\/1758835919854238","volume":"11","author":"R Wesolowski","year":"2019","unstructured":"Wesolowski, R., et al. (2019). Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Therapeutic Advances in Medical Oncology, 11, 1758835919854238.","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10079_CR219","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/JLB.4RI0818-311R","volume":"106","author":"CE Olingy","year":"2019","unstructured":"Olingy, C. E., Dinh, H. Q., & Hedrick, C. C. (2019). Monocyte heterogeneity and functions in cancer. Journal of Leukocyte Biology, 106, 309\u2013322.","journal-title":"Journal of Leukocyte Biology"},{"key":"10079_CR220","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski, N., et al. (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology, 18, 557\u2013564.","journal-title":"Neuro-Oncology"},{"key":"10079_CR221","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","volume":"105","author":"AL Dewar","year":"2005","unstructured":"Dewar, A. L., et al. (2005). Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood, 105, 3127\u20133132.","journal-title":"Blood"},{"key":"10079_CR222","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/jcmm.13326","volume":"22","author":"C Giallongo","year":"2018","unstructured":"Giallongo, C., et al. (2018). Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. Journal of Cellular and Molecular Medicine, 22, 1070\u20131080.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10079_CR223","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.breast.2009.12.001","volume":"19","author":"SL Hines","year":"2010","unstructured":"Hines, S. L., et al. (2010). Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast, 19, 92\u201396.","journal-title":"Breast"},{"key":"10079_CR224","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"Coleman, R., et al. (2014). Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. The Lancet Oncology, 15, 997\u20131006.","journal-title":"The Lancet Oncology"},{"key":"10079_CR225","doi-asserted-by":"publisher","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","volume":"67","author":"C Melani","year":"2007","unstructured":"Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z., & Colombo, M. P. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research, 67, 11438\u201311446.","journal-title":"Cancer Research"},{"key":"10079_CR226","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00262-011-1178-0","volume":"61","author":"MR Porembka","year":"2012","unstructured":"Porembka, M. R., et al. (2012). Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunology, Immunotherapy, 61, 1373\u20131385.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10079_CR227","doi-asserted-by":"publisher","first-page":"797","DOI":"10.4236\/jct.2013.43096","volume":"4","author":"DE Sanford","year":"2013","unstructured":"Sanford, D. E., et al. (2013). A study of zoledronic acid as neo-adjuvant, perioperative therapy in patients with resectable pancreatic ductal adenocarcinoma. Journal of Cancer Therapy, 4, 797\u2013803.","journal-title":"Journal of Cancer Therapy"},{"key":"10079_CR228","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ctrv.2017.06.001","volume":"58","author":"J Molina-Cerrillo","year":"2017","unstructured":"Molina-Cerrillo, J., Alonso-Gordoa, T., Gajate, P., & Grande, E. (2017). Bruton\u2019s tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treatment Reviews, 58, 41\u201350.","journal-title":"Cancer Treatment Reviews"},{"key":"10079_CR229","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","volume":"76","author":"A Stiff","year":"2016","unstructured":"Stiff, A., et al. (2016). Myeloid-derived suppressor cells express Bruton\u2019s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Research, 76, 2125\u20132136.","journal-title":"Cancer Research"},{"key":"10079_CR230","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood-2018-99-114799","volume":"132","author":"G Ferrer","year":"2018","unstructured":"Ferrer, G., et al. (2018). Ibrutinib treatment reduces myeloid derived suppressor cell numbers and function in chronic lymphocytic leukemia. Blood, 132, 239\u2013239.","journal-title":"Blood"},{"key":"10079_CR231","doi-asserted-by":"publisher","first-page":"iv126","DOI":"10.1093\/annonc\/mdz154.001","volume":"30","author":"M Tempero","year":"2019","unstructured":"Tempero, M., et al. (2019). Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: Results from the phase 3 RESOLVE study. Annals of Oncology, 30, iv126.","journal-title":"Annals of Oncology"},{"key":"10079_CR232","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.3390\/ijms21114154","volume":"21","author":"JM Metzler","year":"2020","unstructured":"Metzler, J. M., Burla, L., Fink, D., & Imesch, P. (2020). Ibrutinib in gynecological malignancies and breast cancer: A systematic review. International Journal of Molecular Sciences, 21, 4154.","journal-title":"International Journal of Molecular Sciences"},{"key":"10079_CR233","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000500571","volume":"97","author":"D Hong","year":"2019","unstructured":"Hong, D., et al. (2019). A phase 1b\/2 study of the Bruton tyrosine kinase inhibitor ibrutinib and the PD-L1 inhibitor durvalumab in patients with pretreated solid tumors. Oncology, 97, 102\u2013111.","journal-title":"Oncology"},{"key":"10079_CR234","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1159\/000502383","volume":"110","author":"T Al-Toubah","year":"2020","unstructured":"Al-Toubah, T., et al. (2020). A phase ii study of ibrutinib in advanced neuroendocrine neoplasms. Neuroendocrinology, 110, 377\u2013383.","journal-title":"Neuroendocrinology"},{"key":"10079_CR235","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1200\/JCO.2020.38.15_suppl.3111","volume":"38","author":"B Benner","year":"2020","unstructured":"Benner, B., et al. (2020). A pilot study of Bruton\u2019s tyrosine kinase inhibitor ibrutinib alone and in combination with PD-1 inhibitor nivolumab in patients with metastatic solid tumors. Journal of Clinical Oncology, 38, 3111\u20133111.","journal-title":"Journal of Clinical Oncology"},{"key":"10079_CR236","doi-asserted-by":"publisher","first-page":"147","DOI":"10.18632\/oncoscience.310","volume":"3","author":"D Mass\u00f3-Vall\u00e9s","year":"2016","unstructured":"Mass\u00f3-Vall\u00e9s, D., Jauset, T., & Soucek, L. (2016). Ibrutinib repurposing: From B-cell malignancies to solid tumors. Oncoscience, 3, 147\u2013148.","journal-title":"Oncoscience"},{"key":"10079_CR237","doi-asserted-by":"publisher","first-page":"737943","DOI":"10.3389\/fonc.2021.737943","volume":"11","author":"S Zhu","year":"2021","unstructured":"Zhu, S., et al. (2021). Clinical trials of the BTK inhibitors ibrutinib and acalabrutinib in human diseases beyond B cell malignancies. Frontiers in Oncology, 11, 737943.","journal-title":"Frontiers in Oncology"},{"key":"10079_CR238","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1089\/107999001750277862","volume":"21","author":"S Yokochi","year":"2001","unstructured":"Yokochi, S., et al. (2001). An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2. Journal of Interferon and Cytokine Research, 21, 389\u2013398.","journal-title":"Journal of Interferon and Cytokine Research"},{"key":"10079_CR239","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/cas.14306","volume":"111","author":"T Masuda","year":"2020","unstructured":"Masuda, T., et al. (2020). Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer. Cancer Science, 111, 924\u2013931.","journal-title":"Cancer Science"},{"key":"10079_CR240","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3389\/fonc.2019.01223","volume":"9","author":"RP Tobin","year":"2019","unstructured":"Tobin, R. P., et al. (2019). IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients. Frontiers in Oncology, 9, 1223.","journal-title":"Frontiers in Oncology"},{"key":"10079_CR241","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","volume":"7","author":"M Bilusic","year":"2019","unstructured":"Bilusic, M., et al. (2019). Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. Journal for Immunotherapy of Cancer, 7, 240.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10079_CR242","doi-asserted-by":"crossref","unstructured":"Dominguez, C., McCampbell, K. K., David, J. M., & Palena, C. (2017). Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight, 2: e94296","DOI":"10.1172\/jci.insight.94296"},{"key":"10079_CR243","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny, B., et al. (2020). BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial. Nature Medicine, 26, 878\u2013885.","journal-title":"Nature Medicine"},{"key":"10079_CR244","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1158\/1078-0432.CCR-19-0647","volume":"26","author":"IM Ghobrial","year":"2020","unstructured":"Ghobrial, I. M., et al. (2020). A phase ib\/ii trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma. Clinical Cancer Research, 26, 344\u2013353.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR245","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ccr.2013.10.009","volume":"24","author":"H Katoh","year":"2013","unstructured":"Katoh, H., et al. (2013). CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell, 24, 631\u2013644.","journal-title":"Cancer Cell"},{"key":"10079_CR246","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele, C. W., et al. (2016). CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29, 832\u2013845.","journal-title":"Cancer Cell"},{"key":"10079_CR247","doi-asserted-by":"publisher","first-page":"830208","DOI":"10.3389\/fcell.2022.830208","volume":"10","author":"K Park","year":"2022","unstructured":"Park, K., Veena, M. S., & Shin, D. S. (2022). Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies. Front Cell Dev Biol, 10, 830208.","journal-title":"Front Cell Dev Biol"},{"key":"10079_CR248","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","volume":"26","author":"S Greene","year":"2020","unstructured":"Greene, S., et al. (2020). Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models. Clinical Cancer Research, 26, 1420\u20131431.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR249","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13058-019-1243-8","volume":"22","author":"LJ Goldstein","year":"2020","unstructured":"Goldstein, L. J., et al. (2020). A window-of-opportunity trial of the CXCR1\/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Research, 22, 4.","journal-title":"Breast Cancer Research"},{"key":"10079_CR250","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-16-2748","volume":"23","author":"AF Schott","year":"2017","unstructured":"Schott, A. F., et al. (2017). Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer. Clinical Cancer Research, 23, 5358\u20135365.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR251","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-021-06367-5","volume":"190","author":"LJ Goldstein","year":"2021","unstructured":"Goldstein, L. J., et al. (2021). A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Research and Treatment, 190, 265\u2013275.","journal-title":"Breast Cancer Research and Treatment"},{"key":"10079_CR252","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper, D. J., & Balkwill, F. R. (2022). Harnessing cytokines and chemokines for cancer therapy. Nature Reviews. Clinical Oncology, 19, 237\u2013253.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10079_CR253","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nrc3893","volume":"15","author":"AR Bresnick","year":"2015","unstructured":"Bresnick, A. R., Weber, D. J., & Zimmer, D. B. (2015). S100 proteins in cancer. Nature Reviews Cancer, 15, 96\u2013109.","journal-title":"Nature Reviews Cancer"},{"key":"10079_CR254","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.4049\/jimmunol.181.7.4666","volume":"181","author":"P Sinha","year":"2008","unstructured":"Sinha, P., et al. (2008). Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. The Journal of Immunology, 181, 4666\u20134675.","journal-title":"The Journal of Immunology"},{"key":"10079_CR255","first-page":"223","volume":"7","author":"N Gupta","year":"2014","unstructured":"Gupta, N., Al Ustwani, O., Shen, L., & Pili, R. (2014). Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. Oncology Targets Theraeutics, 7, 223\u2013234.","journal-title":"Oncology Targets Theraeutics"},{"key":"10079_CR256","doi-asserted-by":"publisher","first-page":"e1072672","DOI":"10.1080\/2162402X.2015.1072672","volume":"8","author":"L Shen","year":"2019","unstructured":"Shen, L., & Pili, R. (2019). Tasquinimod targets suppressive myeloid cells in the tumor microenvironment. Oncoimmunology, 8, e1072672.","journal-title":"Oncoimmunology"},{"key":"10079_CR257","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.1158\/1078-0432.CCR-13-1581","volume":"19","author":"AJ Armstrong","year":"2013","unstructured":"Armstrong, A. J., et al. (2013). Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clinical Cancer Research, 19, 6891\u20136901.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR258","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","volume":"34","author":"C Sternberg","year":"2016","unstructured":"Sternberg, C., et al. (2016). Randomized, double-blind, placebo-controlled phase iii study of tasquinimod in men with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 34, 2636\u20132643.","journal-title":"Journal of Clinical Oncology"},{"key":"10079_CR259","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2017.21","volume":"31","author":"EA Eksioglu","year":"2017","unstructured":"Eksioglu, E. A., et al. (2017). Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia, 31, 2172\u20132180.","journal-title":"Leukemia"},{"key":"10079_CR260","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","volume":"28","author":"GS Laszlo","year":"2014","unstructured":"Laszlo, G. S., Estey, E. H., & Walter, R. B. (2014). The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Reviews, 28, 143\u2013153.","journal-title":"Blood Reviews"},{"key":"10079_CR261","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","volume":"34","author":"Y Liu","year":"2019","unstructured":"Liu, Y., Bewersdorf, J. P., Stahl, M., & Zeidan, A. M. (2019). Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Blood Reviews, 34, 67\u201383.","journal-title":"Blood Reviews"},{"key":"10079_CR262","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","volume":"30","author":"P Cheng","year":"2022","unstructured":"Cheng, P., et al. (2022). Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex vivo in MDS and melanoma. Molecular Therapy, 30, 2315\u20132326.","journal-title":"Molecular Therapy"},{"key":"10079_CR263","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJM199105163242002","volume":"324","author":"RP Warrell Jr","year":"1991","unstructured":"Warrell, R. P., Jr., et al. (1991). Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New England Journal of Medicine, 324, 1385\u20131393.","journal-title":"New England Journal of Medicine"},{"key":"10079_CR264","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1158\/0008-5472.CAN-07-2593","volume":"67","author":"Y Nefedova","year":"2007","unstructured":"Nefedova, Y., et al. (2007). Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Research, 67, 11021\u201311028.","journal-title":"Cancer Research"},{"key":"10079_CR265","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.1158\/0008-5472.CAN-06-1690","volume":"66","author":"N Mirza","year":"2006","unstructured":"Mirza, N., et al. (2006). <em>All-trans<\/em>-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Research, 66, 9299\u20139307.","journal-title":"Cancer Research"},{"key":"10079_CR266","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1158\/0008-5472.CAN-07-2593","volume":"67","author":"Y Nefedova","year":"2007","unstructured":"Nefedova, Y., et al. (2007). Mechanism of all-<em>trans<\/em> retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Research, 67, 11021\u201311028.","journal-title":"Cancer Research"},{"key":"10079_CR267","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","volume":"63","author":"RP Tobin","year":"2018","unstructured":"Tobin, R. P., et al. (2018). Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. International Immunopharmacology, 63, 282\u2013291.","journal-title":"International Immunopharmacology"},{"key":"10079_CR268","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.3390\/ijms19092736","volume":"19","author":"W Liu","year":"2018","unstructured":"Liu, W., et al. (2018). The anti-inflammatory effects of vitamin D in tumorigenesis. International Journal Molecular Science, 19, 2736.","journal-title":"International Journal Molecular Science"},{"key":"10079_CR269","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.humimm.2010.04.008","volume":"71","author":"JE Walsh","year":"2010","unstructured":"Walsh, J. E., Clark, A.-M., Day, T. A., Gillespie, M. B., & Young, M. R. I. (2010). Use of \u03b1,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Human Immunology, 71, 659\u2013665.","journal-title":"Human Immunology"},{"key":"10079_CR270","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1158\/1538-7445.AM2019-2364","volume":"79","author":"JC Fleet","year":"2019","unstructured":"Fleet, J. C., Burcham, G. N., Calvert, R., & Ratliff, T. L. (2019). Abstract 2364: 1\u03b1, 25 dihydroxyvitamin D (1,25(OH)<sub>2<\/sub>D) inhibits the T cell suppressive function of myeloid derived suppressor sells (MDSC). Cancer Research, 79, 2364\u20132364.","journal-title":"Cancer Research"},{"key":"10079_CR271","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00262-003-0459-7","volume":"53","author":"DMR Lathers","year":"2004","unstructured":"Lathers, D. M. R., Clark, J. I., Achille, N. J., & Young, M. R. I. (2004). Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunology, Immunotherapy, 53, 422\u2013430.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10079_CR272","doi-asserted-by":"crossref","unstructured":"Henderson Berg, M. H., Del Rincon, S. V. & Miller, W. H. (2022). Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: From monoclonal antibodies to kinase inhibition. Journal Immunotherapy Cancer, 10, e003551","DOI":"10.1136\/jitc-2021-003551"},{"key":"10079_CR273","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/mc.22767","volume":"57","author":"JF Liu","year":"2018","unstructured":"Liu, J. F., et al. (2018). Inhibition of JAK2\/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer. Molecular Carcinogenesis, 57, 429\u2013439.","journal-title":"Molecular Carcinogenesis"},{"key":"10079_CR274","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjh.13373","volume":"169","author":"S Parampalli Yajnanarayana","year":"2015","unstructured":"Parampalli Yajnanarayana, S., et al. (2015). JAK1\/2 inhibition impairs T cell function in\u00a0vitro and in patients with myeloproliferative neoplasms. British Journal of Haematology, 169, 824\u2013833.","journal-title":"British Journal of Haematology"},{"key":"10079_CR275","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1016\/j.cllc.2018.03.016","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone, G., et al. (2018). A placebo-controlled phase ii study of ruxolitinib in combination with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non\u2013small-cell lung cancer and systemic inflammation. Clinical Lung Cancer, 19, e567\u2013e574.","journal-title":"Clinical Lung Cancer"},{"key":"10079_CR276","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1200\/JCO.2015.61.4578","volume":"33","author":"HI Hurwitz","year":"2015","unstructured":"Hurwitz, H. I., et al. (2015). Randomized, double-blind, phase ii study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. Journal of Clinical Oncology, 33, 4039\u20134047.","journal-title":"Journal of Clinical Oncology"},{"key":"10079_CR277","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S., et al. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366, 799\u2013807.","journal-title":"New England Journal of Medicine"},{"key":"10079_CR278","doi-asserted-by":"publisher","first-page":"e1196312","DOI":"10.1080\/2162402X.2016.1196312","volume":"5","author":"N de Haas","year":"2016","unstructured":"de Haas, N., de Koning, C., Spilgies, L., de Vries, I. J. M., & Hato, S. V. (2016). Improving cancer immunotherapy by targeting the STATe of MDSCs. OncoImmunology, 5, e1196312.","journal-title":"OncoImmunology"},{"key":"10079_CR279","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1634\/theoncologist.2016-0197","volume":"22","author":"RJ Motzer","year":"2017","unstructured":"Motzer, R. J., Escudier, B., Gannon, A., & Figlin, R. A. (2017). Sunitinib: Ten years of successful clinical use and study in advanced renal cell carcinoma. The Oncologist, 22, 41\u201352.","journal-title":"The Oncologist"},{"key":"10079_CR280","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.intimp.2011.01.030","volume":"11","author":"J Finke","year":"2011","unstructured":"Finke, J., et al. (2011). MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. International Immunopharmacology, 11, 856\u2013861.","journal-title":"International Immunopharmacology"},{"key":"10079_CR281","first-page":"587","volume":"17","author":"E Jonasch","year":"2019","unstructured":"Jonasch, E. (2019). NCCN guidelines updates: Management of metastatic kidney cancer. Journal of the National Comprehensive Cancer Network, 17, 587\u2013589.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10079_CR282","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko, J. S., et al. (2009). Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clinical Cancer Research, 15, 2148\u20132157.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR283","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1158\/1078-0432.CCR-14-2742","volume":"21","author":"HM Chen","year":"2015","unstructured":"Chen, H. M., et al. (2015). Myeloid-derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy. Clinical Cancer Research, 21, 4073\u20134085.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR284","doi-asserted-by":"publisher","first-page":"E934","DOI":"10.1210\/jc.2011-3428","volume":"97","author":"JD French","year":"2012","unstructured":"French, J. D., et al. (2012). Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 97, E934-943.","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10079_CR285","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/2326-6066.CIR-14-0201","volume":"3","author":"JJ Severson","year":"2015","unstructured":"Severson, J. J., et al. (2015). PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer. Cancer Immunology Research, 3, 620\u2013630.","journal-title":"Cancer Immunology Research"},{"key":"10079_CR286","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1242\/jcs.042762","volume":"122","author":"M Huse","year":"2009","unstructured":"Huse, M. (2009). The T-cell-receptor signaling network. Journal of Cell Science, 122, 1269\u20131273.","journal-title":"Journal of Cell Science"},{"key":"10079_CR287","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L., & Flies, D. B. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews Immunology, 13, 227\u2013242.","journal-title":"Nature Reviews Immunology"},{"key":"10079_CR288","doi-asserted-by":"publisher","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","volume":"2","author":"C Granier","year":"2017","unstructured":"Granier, C., et al. (2017). Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open, 2, e000213.","journal-title":"ESMO Open"},{"key":"10079_CR289","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364, 2517\u20132526.","journal-title":"New England Journal of Medicine"},{"key":"10079_CR290","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens, A., et al. (2016). Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clinical Cancer Research, 22, 2908\u20132918.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR291","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt, C., et al. (2015). Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clinical Cancer Research, 21, 5453\u20135459.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR292","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/2326-6066.CIR-13-0016","volume":"1","author":"YP de Coa\u00f1a","year":"2013","unstructured":"de Coa\u00f1a, Y. P., et al. (2013). Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their arginase1 production. Cancer Immunology Research, 1, 158\u2013162.","journal-title":"Cancer Immunology Research"},{"key":"10079_CR293","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00262-014-1570-7","volume":"63","author":"Y Pico de Coa\u00f1a","year":"2014","unstructured":"Pico de Coa\u00f1a, Y., Masucci, G., Hansson, J., & Kiessling, R. (2014). Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. Cancer Immunology, Immunotherapy, 63, 977\u2013983.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10079_CR294","doi-asserted-by":"publisher","first-page":"21539","DOI":"10.18632\/oncotarget.15368","volume":"8","author":"Y Pico de Coana","year":"2017","unstructured":"Pico de Coana, Y., et al. (2017). Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget, 8, 21539.","journal-title":"Oncotarget"},{"key":"10079_CR295","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","volume":"63","author":"C Meyer","year":"2014","unstructured":"Meyer, C., et al. (2014). Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunology, Immunotherapy, 63, 247\u2013257.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10079_CR296","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11523-018-0595-9","volume":"13","author":"A Tzeng","year":"2018","unstructured":"Tzeng, A., et al. (2018). Immunological correlates of response to immune checkpoint inhibitors in metastatic urothelial carcinoma. Targeted Oncology, 13, 599\u2013609.","journal-title":"Targeted Oncology"},{"key":"10079_CR297","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/scitranslmed.3007974","volume":"6","author":"SL Highfill","year":"2014","unstructured":"Highfill, S. L., et al. (2014). Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med, 6, 237\u2013267.","journal-title":"Sci Transl Med"},{"key":"10079_CR298","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau, O., et al. (2016). Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature, 539, 443\u2013447.","journal-title":"Nature"},{"key":"10079_CR299","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1126\/scitranslmed.3003130","volume":"3","author":"S Amarnath","year":"2011","unstructured":"Amarnath, S., et al. (2011). The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med, 3, 111\u2013120.","journal-title":"Sci Transl Med"},{"key":"10079_CR300","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi, A., et al. (2022). Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling: CCS, 20, 44.","journal-title":"Cell Communication and Signaling: CCS"},{"key":"10079_CR301","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","volume":"28","author":"LP Andrews","year":"2022","unstructured":"Andrews, L. P., et al. (2022). Molecular pathways and mechanisms of LAG-3 in cancer therapy. Clinical Cancer Research, 28, 5030.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR302","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/imcb.12054","volume":"96","author":"SM Toor","year":"2018","unstructured":"Toor, S. M., & Elkord, E. (2018). Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer. Immunology and Cell Biology, 96, 888\u2013897.","journal-title":"Immunology and Cell Biology"},{"key":"10079_CR303","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.4161\/hv.29847","volume":"10","author":"A Fern\u00e1ndez","year":"2014","unstructured":"Fern\u00e1ndez, A., et al. (2014). Adjuvants and myeloid-derived suppressor cells: Enemies or allies in therapeutic cancer vaccination. Human Vaccines & Immunotherapeutics, 10, 3251\u20133260.","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10079_CR304","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1038\/sj.onc.1206459","volume":"22","author":"G Dranoff","year":"2003","unstructured":"Dranoff, G. (2003). GM-CSF-secreting melanoma vaccines. Oncogene, 22, 3188\u20133192.","journal-title":"Oncogene"},{"key":"10079_CR305","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","volume":"25","author":"EA Mittendorf","year":"2019","unstructured":"Mittendorf, E. A., et al. (2019). Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: A randomized, multicenter, phase III clinical trial. Clinical Cancer Research, 25, 4248\u20134254.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR306","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/imt.14.22","volume":"6","author":"EJ Schneble","year":"2014","unstructured":"Schneble, E. J., et al. (2014). The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax\u2122) in breast cancer patients at risk for recurrence: Correlation of immunologic data with clinical response. Immunotherapy, 6, 519\u2013531.","journal-title":"Immunotherapy"},{"key":"10079_CR307","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1158\/0008-5472.CAN-04-0757","volume":"64","author":"P Serafini","year":"2004","unstructured":"Serafini, P., et al. (2004). High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Research, 64, 6337\u20136343.","journal-title":"Cancer Research"},{"key":"10079_CR308","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/CJI.0b013e31826b20b6","volume":"35","author":"PL Triozzi","year":"2012","unstructured":"Triozzi, P. L., et al. (2012). Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte\/macrophage colony stimulating factor. Journal of Immunotherapy, 35, 587\u2013594.","journal-title":"Journal of Immunotherapy"},{"key":"10079_CR309","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-17-3757","volume":"24","author":"S Khanna","year":"2018","unstructured":"Khanna, S., et al. (2018). Tumor-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients. Clinical Cancer Research, 24, 2859\u20132872.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR310","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1349-7006.2007.00429.x","volume":"98","author":"H Yanagimoto","year":"2007","unstructured":"Yanagimoto, H., et al. (2007). Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Science, 98, 605\u2013611.","journal-title":"Cancer Science"},{"key":"10079_CR311","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1517\/14712598.2010.484801","volume":"10","author":"AA Chiappori","year":"2010","unstructured":"Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., & Gabrilovich, D. I. (2010). INGN-225: A dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: Observed association between immune response and enhanced chemotherapy effect. Expert Opinion on Biological Therapy, 10, 983\u2013991.","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10079_CR312","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","volume":"12","author":"SJ Antonia","year":"2006","unstructured":"Antonia, S. J., et al. (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clinical Cancer Research, 12, 878\u2013887.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR313","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1158\/1078-0432.CCR-17-2709","volume":"24","author":"NR Hardwick","year":"2018","unstructured":"Hardwick, N. R., et al. (2018). p53-Reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy. Clinical Cancer Research, 24, 1315\u20131325.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR314","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","volume":"77","author":"GC Prendergast","year":"2017","unstructured":"Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017). Discovery of IDO1 inhibitors: From bench to bedside. Cancer Research, 77, 6795\u20136811.","journal-title":"Cancer Research"},{"key":"10079_CR315","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.3390\/cancers12102831","volume":"12","author":"M Gamat-Huber","year":"2020","unstructured":"Gamat-Huber, M., et al. (2020). Treatment combinations with DNA vaccines for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Cancers (Basel), 12, 2831.","journal-title":"Cancers (Basel)"},{"key":"10079_CR316","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-021-01156-5","volume":"14","author":"JA Park","year":"2021","unstructured":"Park, J. A., Wang, L., & Cheung, N. V. (2021). Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. Journal of Hematology & Oncology, 14, 142.","journal-title":"Journal of Hematology & Oncology"},{"key":"10079_CR317","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008). Immunological aspects of cancer chemotherapy. Nature Reviews Immunology, 8, 59\u201373.","journal-title":"Nature Reviews Immunology"},{"key":"10079_CR318","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-014-0030-4","volume":"2","author":"H Matsushita","year":"2014","unstructured":"Matsushita, H., et al. (2014). A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. Journal for Immunotherapy of Cancer, 2, 30.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10079_CR319","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","volume":"9","author":"V Fleming","year":"2018","unstructured":"Fleming, V., et al. (2018). Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Frontiers in Immunology, 9, 398.","journal-title":"Frontiers in Immunology"},{"key":"10079_CR320","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3389\/fimmu.2020.00783","volume":"11","author":"A Hou","year":"2020","unstructured":"Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020). Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Frontiers in Immunology, 11, 783.","journal-title":"Frontiers in Immunology"},{"key":"10079_CR321","doi-asserted-by":"publisher","first-page":"e14159","DOI":"10.1200\/JCO.2019.37.15_suppl.e14159","volume":"37","author":"N Parker","year":"2019","unstructured":"Parker, N., Al-Obaidi, A., Truong, Q. V., & Badgett, R. (2019). Pembrolizumab versus the standard of care for cancer therapy: A meta-analysis of 12 KEYNOTE trials comparing overall survival. Journal of Clinical Oncology, 37, e14159\u2013e14159.","journal-title":"Journal of Clinical Oncology"},{"key":"10079_CR322","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1200\/JCO.2020.38.15_suppl.3111","volume":"38","author":"B Benner","year":"2020","unstructured":"Benner, B., et al. (2020). A pilot study of Bruton\u2019s tyrosine kinase inhibitor ibrutinib alone and in combination with PD-1 inhibitor nivolumab in patients with metastatic solid tumors. Journal of Clinical Oncology, 38, 3111\u20133111.","journal-title":"Journal of Clinical Oncology"},{"key":"10079_CR323","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bjh.17282","volume":"192","author":"H Chen","year":"2021","unstructured":"Chen, H., et al. (2021). Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. British Journal of Haematology, 192, 568\u2013576.","journal-title":"British Journal of Haematology"},{"key":"10079_CR324","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.3390\/ijms23105837","volume":"23","author":"JC Wang","year":"2022","unstructured":"Wang, J. C., & Sun, L. (2022). PD-1\/PD-L1, MDSC pathways, and checkpoint inhibitor therapy in Ph(-) myeloproliferative neoplasm: A review. International Journal of Molecular Sciences, 23, 5837.","journal-title":"International Journal of Molecular Sciences"},{"key":"10079_CR325","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00262-018-2288-8","volume":"68","author":"CM Huijts","year":"2019","unstructured":"Huijts, C. M., et al. (2019). The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: Results from a phase I clinical trial. Cancer Immunology, Immunotherapy, 68, 503\u2013515.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10079_CR326","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1158\/1078-0432.CCR-21-3726","volume":"28","author":"DM Girardi","year":"2022","unstructured":"Girardi, D. M., et al. (2022). Cabozantinib plus nivolumab phase i expansion study in patients with metastatic urothelial carcinoma refractory to immune checkpoint inhibitor therapy. Clinical Cancer Research, 28, 1353\u20131362.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR327","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1016\/j.cllc.2020.10.018","volume":"22","author":"DH Owen","year":"2021","unstructured":"Owen, D. H., et al. (2021). Deep and durable response to nivolumab and temozolomide in small-cell lung cancer associated with an early decrease in myeloid-derived suppressor cells. Clinical Lung Cancer, 22, e487\u2013e497.","journal-title":"Clinical Lung Cancer"},{"key":"10079_CR328","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.cell.2017.12.026","volume":"172","author":"MF Tavazoie","year":"2018","unstructured":"Tavazoie, M. F., et al. (2018). LXR\/ApoE activation restricts innate immune suppression in cancer. Cell, 172, 825\u2013840.","journal-title":"Cell"},{"key":"10079_CR329","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","volume":"203","author":"P Serafini","year":"2006","unstructured":"Serafini, P., et al. (2006). Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Journal of Experimental Medicine, 203, 2691\u20132702.","journal-title":"Journal of Experimental Medicine"},{"key":"10079_CR330","doi-asserted-by":"publisher","first-page":"175883591985423","DOI":"10.1177\/1758835919854238","volume":"11","author":"R Wesolowski","year":"2019","unstructured":"Wesolowski, R., et al. (2019). Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol, 11, 1758835919854238.","journal-title":"Ther Adv Med Oncol"},{"key":"10079_CR331","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1756287215603558","volume":"8","author":"AR Mehta","year":"2016","unstructured":"Mehta, A. R., & Armstrong, A. J. (2016). Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects. Therapeutic Advances in Urology, 8, 9\u201318.","journal-title":"Therapeutic Advances in Urology"},{"key":"10079_CR332","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.3390\/cancers13246293","volume":"13","author":"K Bullock","year":"2021","unstructured":"Bullock, K., & Richmond, A. (2021). Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy. Cancers (Basel), 13, 6293.","journal-title":"Cancers (Basel)"},{"key":"10079_CR333","doi-asserted-by":"crossref","unstructured":"Overman, M., et al. (2020). Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Journal Immunotherapy Cancer, 8, e000587","DOI":"10.1136\/jitc-2020-000587"},{"key":"10079_CR334","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/JLB.4A0720-409RR","volume":"110","author":"M Jontvedt Jorgensen","year":"2021","unstructured":"Jontvedt Jorgensen, M., et al. (2021). Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors. Journal Leukocyte Biology, 110, 177\u2013186.","journal-title":"Journal Leukocyte Biology"},{"key":"10079_CR335","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/imt.14.22","volume":"6","author":"EJ Schneble","year":"2014","unstructured":"Schneble, E. J., et al. (2014). The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax) in breast cancer patients at risk for recurrence: Correlation of immunologic data with clinical response. Immunotherapy, 6, 519\u2013531.","journal-title":"Immunotherapy"},{"key":"10079_CR336","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1517\/14712598.2010.484801","volume":"10","author":"AA Chiappori","year":"2010","unstructured":"Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., & Gabrilovich, D. I. (2010). INGN-225: A dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: Observed association between immune response and enhanced chemotherapy effect. Expert Opinion Biology Therapeutics, 10, 983\u2013991.","journal-title":"Expert Opinion Biology Therapeutics"},{"key":"10079_CR337","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","volume":"12","author":"SJ Antonia","year":"2006","unstructured":"Antonia, S. J., et al. (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clinical Cancer Research, 12, 878\u2013887.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR338","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1158\/1078-0432.CCR-17-2709","volume":"24","author":"NR Hardwick","year":"2018","unstructured":"Hardwick, N. R., et al. (2018). p53-Reactive t cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy. Clinical Cancer Research, 24, 1315\u20131325.","journal-title":"Clinical Cancer Research"},{"key":"10079_CR339","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jtho.2016.04.026","volume":"11","author":"F Koinis","year":"2016","unstructured":"Koinis, F., et al. (2016). Effect of first-line treatment on myeloid-derived suppressor cells\u2019 subpopulations in the peripheral blood of patients with non-small cell lung cancer. Journal of Thoracic Oncology, 11, 1263\u20131272.","journal-title":"Journal of Thoracic Oncology"},{"key":"10079_CR340","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jtho.2018.03.032","volume":"13","author":"PH Feng","year":"2018","unstructured":"Feng, P. H., et al. (2018). Bevacizumab reduces S100A9-positive MDSCs linked to intracranial control in patients with EGFR-mutant lung adenocarcinoma. Journal of Thoracic Oncology, 13, 958\u2013967.","journal-title":"Journal of Thoracic Oncology"},{"key":"10079_CR341","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4049\/jimmunol.163.1.507","volume":"163","author":"TM Clay","year":"1999","unstructured":"Clay, T. M., et al. (1999). Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. The Journal of Immunology, 163, 507\u2013513.","journal-title":"The Journal of Immunology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-023-10079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-023-10079-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-023-10079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:29:55Z","timestamp":1744158595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-023-10079-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":341,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10079"],"URL":"https:\/\/doi.org\/10.1007\/s10555-023-10079-1","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]},"assertion":[{"value":"10 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this was a review, no animal or human specimens were involved in the writing of the review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}